Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10512113 | 0.85 | SLC6A4 (0.47) | SLC6A4SLC6A3NPC1RAB9ACASP3 | |
| SCHEMBL2708451 | 0.82 | SLC6A4 (0.51) | SLC6A4SLC6A3NPC1RAB9ACASP3 | |
| SCHEMBL30301996 | 0.82 | SLC6A4 (0.51) | SLC6A4SLC6A3NPC1RAB9ACASP3 | |
| SCHEMBL523258 | 0.81 | CES2 (0.61) | SLC6A4SLC6A3NPC1RAB9ACASP3 | |
| SCHEMBL14012584 | 0.81 | CES2 (0.61) | SLC6A4SLC6A3NPC1RAB9ACASP3 | |
| SCHEMBL23607068 | 0.79 | SLC6A4 (0.49) | SLC6A4SLC6A3NPC1RAB9ACASP3 | |
| SCHEMBL109588 | 0.79 | CA12 (0.67) | SLC6A4SLC6A3NPC1RAB9ACASP3 | |
| SCHEMBL804379 | 0.79 | NR4A2 (0.50) | CFTRCA12CA1CA2CA7 | |
| SCHEMBL1097161 | 0.79 | NPC1 (0.51) | SLC6A4SLC6A3NPC1RAB9ACASP3 | |
| SCHEMBL17080159 | 0.79 | KDM4E (0.62) | SMN1; SMN2CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20230044112-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230044112-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-2742039-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN-LA ROCHE INC. | 2013-08-01 | — | — | US | disclosed |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN-LA ROCHE INC. | 2013-08-01 | — | — | US | disclosed |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN-LA ROCHE INC. | 2013-08-01 | — | — | US | disclosed |
| WO-2013020993-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | WO | disclosed |
| WO-2013020993-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | WO | disclosed |
| US-20090029975-A1 | 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090029975-A1 | 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090029975-A1 | 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1897880-A1 | 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029975-A1 | 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF | MIF, CCL2, MSR1 | SLC6A4 1898/4885SLC6A3 1014/4885NPC1 819/4885 |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | CFTR, H1-10, RECQL | SLC6A4 1038/4885SLC6A3 1189/4885NPC1 1418/4885 |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | SLC6A4 4474/4885SLC6A3 4731/4885NPC1 447/4885 |
| US-20230044112-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | SLC6A4 4474/4885SLC6A3 4731/4885NPC1 447/4885 |
| US-11814376-B2 | Hepatitis b core protein modulators | HAVCR2, FABP1, MAVS | SLC6A4 4474/4885SLC6A3 4731/4885NPC1 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.